Imugene Ltd · ASX:IMU

Imugene — FINSIA Healthcare Forum (June 2007)

14 slides from Imugene's conference presentation, June 2007

  1. Slide 1: Imugene: Animal Health Biological Products

    Slide 1: Imugene: Animal Health Biological Products

    IMUGENE Animal Health Biological Products June 2007 Dr Warwick Lamb Managing Director

  2. Slide 2: Poultry productivity enhancer

    Slide 2: Poultry productivity enhancer

    1. Poultry productivity enhancer – Trial results show increased poultry growth up to 15% (antibiotics <4%) – Two Australian safety trials completed – Licensed to Merial in Oct 2005 – Sign-up fees & milestone payment so far – Progressing through product development for sale to the global markets

  3. Slide 3: Avian influenza vaccine for poultry

    Slide 3: Avian influenza vaccine for poultry

    2. Avian influenza vaccine for poultry – Proof of concept trials in Jan 2007 – May 2007 trials - results of up to 100% efficacy in US trials – Govt grant of $882,000 – Strong international interest – Major licensing opportunity

  4. Slide 4: Commercial success

    Slide 4: Commercial success

    Commercial success • Advanced products with market need • Early licensing success • Early regulatory approvals • Team with successful product commercialisation track records eg Pfizer, Smith Kline Beecham • Strong product pipeline • Proven & patented platform science

  5. Slide 5: Competitive advantages

    Slide 5: Competitive advantages

    Competitive advantages • Strong platform for product portfolio • Easy to administer (feed, water or aerosol) • Do not require injection or animal handling • Suitable for in ovo injection (into the egg) • Inexpensive to manufacture • Safe – No cross species infection – Residue free in animal – No gen

  6. Slide 6: Competitive advantages

    Slide 6: Competitive advantages

    Competitive advantages • Large global markets • Biologicals – shorter regulatory timeframes – US Dept of Agriculture – not FDA – Quicker to market and revenues than human drugs – Longer revenue stream under patent • Residue free and non-chemical treatments

  7. Slide 7: Other products under development

    Slide 7: Other products under development

    Other products under development Strong product pipeline 1. Poultry Productivity Enhancer 2. Avian Influenza Vaccines 3. Coccidiosis vaccine 4. PRRS vaccine 5. PAV treatment

  8. Slide 8: Coccidiosis vaccine

    Slide 8: Coccidiosis vaccine

    Coccidiosis vaccine • Contract to construct vaccine candidates for Teva/Abic • Vaccine candidates completed • Expect handover to Teva/Abic for poultry trials in 2007 • Anticipate licensing FAV for delivery of these vaccines if successful in trials

  9. Slide 9: Pig vaccines

    Slide 9: Pig vaccines

    Pig vaccines – PRRS vaccine • World’s most damaging pig disease • Market US$200m-$400m pa • No effective vaccine in the market • Successful pig trials and being fast-tracked with further US trials – PAV-Merial – respiratory disease • Market US$300m pa • Evaluated by Merial for major markets – Other

  10. Slide 10: Commercial agreements summary

    Slide 10: Commercial agreements summary

    Commercial agreements summary • First product licensed to Merial (Merck and sanofi- aventis) – world leading animal health company (US$2B pa sales) • Product agreement with Abic (Teva pharmaceuticals – global Top 20) to develop chicken vaccine for coccidiosis (US$850m market ) • Product development

  11. Slide 11: Company progression

    Slide 11: Company progression

    Company progression • Develop poultry and pig product portfolio – Range of PAV & FAV based vaccines – Progress each vaccine candidate • Vaccine candidate construction – Australia • Clinical trials – US and Europe • Expand international commercial alliances • Flexible commercialisation strategy

  12. Slide 12: Financials

    Slide 12: Financials

    Financials • Net cash outflow – $150k/mth • Merial funding development work on poultry productivity enhancer • $1.4m cash – March 07 • $880k Government grant for bird flu – 2 years • Financial returns from Merial • Contract payments due from Teva/Abic • Teva/Abic to fund trials & product development

  13. Slide 13: Corporate

    Slide 13: Corporate

    Corporate • Directors & management – Graham Dowland – Chairman – Warwick Lamb – CEO – Roger Steinepreis – Director – Mike Sheppard – Chief Scientific Officer • Shares on issue 130.5 m (Board – 13%) • Options on issue – Expiry 31 Dec 09 (25c) 4.35 m – Expiry 31 Oct 07 (22.5c) 4.63 m – Expiry 31 Oct 0

  14. Slide 14: Key points

    Slide 14: Key points

    Key points • Very high efficacy in lead products • Products with substantial commercial advantages • Large global markets • Products at advances stages • Potential to expand markets with new products • Multiple commercialisation strategies • Multinational pharmaceutical validation – including Merial

Source: Internet Archive copy of imugene.com

More decks from Imugene Ltd

All 54 Imugene decks